Literature DB >> 26428870

Rethinking the old antiviral drug moroxydine: Discovery of novel analogues as anti-hepatitis C virus (HCV) agents.

Andrea Magri1, Roisin Reilly2, Nicolò Scalacci2, Marco Radi3, Michael Hunter2, Manon Ripoll2, Arvind H Patel4, Daniele Castagnolo5.   

Abstract

The discovery of a novel class of HCV inhibitors is described. The new amidinourea compounds were designed as isosteric analogues of the antiviral drug moroxydine. The two derivatives 11g and 11h showed excellent HCV inhibition activity and viability and proved to inhibit a step(s) of the RNA replication. The new compounds have been synthesized in only three synthetic steps from cheap building blocks and in high yields, thus turning to be promising drug candidates in the development of cheaper HCV treatments.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amidinourea; Guanidine; HCV; Hepatitis C life cycle; RNA replication

Mesh：

Substances：

Year:  2015        PMID： 26428870     DOI： 10.1016/j.bmcl.2015.09.029

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  6 in total

1.  An efficient synthesis of indolo[2,3-b]quinoline guanidine derivatives with their in vitro and in vivo study.

Authors:  Katarzyna Sidoryk; Marta Świtalska; Piotr Rózga; Joanna Wietrzyk; Iwona Bujak; Bartłomiej Żerek; Łukasz Kaczmarek; Marcin Cybulski
Journal:  Med Chem Res       Date:  2017-09-05       Impact factor: 1.965

2.  17,β-estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle.

Authors:  Andrea Magri; Matteo N Barbaglia; Chiara Z Foglia; Elisa Boccato; Michela E Burlone; Sarah Cole; Paola Giarda; Elena Grossini; Arvind H Patel; Rosalba Minisini; Mario Pirisi
Journal:  Liver Int       Date:  2016-11-25       Impact factor: 5.828

3.  Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.

Authors:  Mahmoud Kandeel; Alaa H M Abdelrahman; Kentaro Oh-Hashi; Abdelazim Ibrahim; Katharigatta N Venugopala; Mohamed A Morsy; Mahmoud A A Ibrahim
Journal:  J Biomol Struct Dyn       Date:  2020-06-29

4.  Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.

Authors:  David Smith; Andrea Magri; David Bonsall; Camilla L C Ip; Amy Trebes; Anthony Brown; Palo Piazza; Rory Bowden; Dung Nguyen; M Azim Ansari; Peter Simmonds; Eleanor Barnes
Journal:  Hepatology       Date:  2018-04-27       Impact factor: 17.425

5.  Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus.

Authors:  M Azim Ansari; Vincent Pedergnana; Camilla L C Ip; Andrea Magri; Annette Von Delft; David Bonsall; Nimisha Chaturvedi; Istvan Bartha; David Smith; George Nicholson; Gilean McVean; Amy Trebes; Paolo Piazza; Jacques Fellay; Graham Cooke; Graham R Foster; Emma Hudson; John McLauchlan; Peter Simmonds; Rory Bowden; Paul Klenerman; Eleanor Barnes; Chris C A Spencer
Journal:  Nat Genet       Date:  2017-04-10       Impact factor: 41.307

6.  In Vitro and In Vivo Inhibition of the Mycobacterium tuberculosis Phosphopantetheinyl Transferase PptT by Amidinoureas.

Authors:  Samantha Ottavi; Sarah M Scarry; John Mosior; Yan Ling; Julia Roberts; Amrita Singh; David Zhang; Laurent Goullieux; Christine Roubert; Eric Bacqué; H Rachel Lagiakos; Jeremie Vendome; Francesca Moraca; Kelin Li; Andrew J Perkowski; Remya Ramesh; Matthew M Bowler; William Tracy; Victoria A Feher; James C Sacchettini; Ben S Gold; Carl F Nathan; Jeffrey Aubé
Journal:  J Med Chem       Date:  2022-01-19       Impact factor: 8.039
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.